European committee says Lilly Alzheimer’s drug shouldn’t get marketing approval
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it ...
Medscape2d
Alzheimer Drug Donanemab Gets No-Go From European Regulator
The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...
KOB 42d
European committee says Lilly Alzheimer’s drug shouldn’t get marketing approval
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it. The agency’s Committee ...
Ibj.com4d
European regulators says Lilly Alzheimer’s drug shouldn’t get marketing approval
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it. The agency’s Committee ...
WTHR3d
European committee says Lilly Alzheimer's drug shouldn't get marketing approval
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it. The agency’s Committee for ...